Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Lupus ; 23(3): 273-83, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24356612

ABSTRACT

OBJECTIVES: The aim of the Systemic LUpus Erythematosus Cost of Care In Europe (LUCIE) study was to evaluate the annual direct medical costs of managing adults with active autoantibody-positive disease on medication for SLE in secondary care. This paper presents the UK analyses only. METHODS: A cost-of-illness study was conducted from the perspective of the National Health Service. Health resource utilization data were retrieved over a two-year period from four centres in England and unit cost data were taken from published sources. RESULTS: At baseline, 86 patients were included, 38 (44.2%) had severe SLE and 48 (55.8%) had non-severe SLE. The mean (SD) SELENA-SLEDAI score was 7.7 (5.7). The mean (SD) annual direct medical cost of was estimated at £3231 (£2333) per patient and was 2.2 times higher in patients with severe SLE compared with patients with non-severe SLE (p < 0.001). Multivariate model analyses showed that renal disease involvement (p = 0.0016) and severe flares (p = 0.0001) were associated with higher annual direct costs. CONCLUSIONS: Improvement of the overall stability of SLE and early intervention to minimize the impact of renal disease may be two approaches to mitigate the long-term direct cost of managing SLE patients in the UK.


Subject(s)
Autoantibodies/blood , Health Care Costs , Lupus Erythematosus, Systemic/economics , Lupus Erythematosus, Systemic/therapy , Outcome and Process Assessment, Health Care/economics , State Medicine/economics , Adult , Biomarkers/blood , Cost Control , Cost-Benefit Analysis , Disease Progression , Female , Humans , Lupus Erythematosus, Systemic/blood , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/epidemiology , Lupus Erythematosus, Systemic/immunology , Lupus Nephritis/blood , Lupus Nephritis/diagnosis , Lupus Nephritis/economics , Lupus Nephritis/therapy , Male , Middle Aged , Models, Economic , Multivariate Analysis , Prevalence , Retrospective Studies , Severity of Illness Index , Time Factors , Treatment Outcome , United Kingdom/epidemiology
2.
Case Rep Cardiol ; 2012: 486427, 2012.
Article in English | MEDLINE | ID: mdl-24826256

ABSTRACT

Introduction. Left ventricular outflow obstruction might be part of the pathophysiological mechanism of Tako-tsubo cardiomyopathy. This obstruction can be masked by Tako-tsubo cardiomyopathy and diagnosed only by followup. Case Presentation. A 70-year-old female presented with Tako-tsubo cardiomyopathy and masked obstructive hypertrophic cardiomyopathy at presentation. Conclusion. Tako-tsubo cardiomyopathy typically presents like an acute MI and is characterized by severe, but transient, regional left ventricular systolic dysfunction. Prompt evaluation of the coronary status is, therefore, mandatory. The prognosis under medical treatment of heart failure symptoms and watchful waiting is favourable. Previous studies showed that LVOT obstruction might be part of the pathophysiological mechanism of TCM. This paper supports this theory. However, TCM may also mask any preexisting LVOT obstruction.

3.
Lupus ; 18(6): 479-85, 2009 May.
Article in English | MEDLINE | ID: mdl-19395448

ABSTRACT

Individuals with systemic lupus erythematosus (SLE) have an increased susceptibility to certain types of cancer. Of particular concern are haematologic malignancies, specifically non-Hodgkin lymphoma, where a three- to four-fold increased risk is seen in SLE, compared with the general population. There is some evidence that immunosuppressive exposures play a role, although there appear to be other factors driving the risk. Lupus disease activity, with resultant dysregulated lymphocyte proliferation, may itself be a mediator of the association between SLE and lymphoma. Aside from haematologic malignancy risk, lung cancer also is increased in SLE compared with the general population, and smoking likely drives this risk in large part. Last but not least, cervical dysplasia is a concern in women with SLE, particularly with exposure to immunosuppressants; routine screening for this complication should not be neglected.


Subject(s)
Lupus Erythematosus, Systemic , Neoplasms , Humans , Immunity, Cellular , Incidence , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/diagnosis , Lupus Erythematosus, Systemic/epidemiology , Neoplasms/diagnosis , Neoplasms/epidemiology , Neoplasms/etiology , Prevalence , Risk Factors
4.
Rheumatology (Oxford) ; 46(11): 1634-40, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17623748

ABSTRACT

Pregnancy is an issue that should be discussed with all patients with rheumatic diseases who are in the reproductive age group. Infertility is rarely due to the disease but can be associated with cyclophosphamide therapy. Most rheumatic diseases that are well controlled prior to pregnancy do not deteriorate in pregnancy, providing that the patient continues with appropriate disease-modifying therapy. Some patients with inflammatory arthritis go in to remission during pregnancy. Patients with renal involvement may be at increased risk of disease flare. This needs to be distinguished from pre-eclampsia. Intrauterine growth restriction is more likely in patients with active systemic disease, hypertension, a history of thrombosis and renal involvement. Premature delivery may need to be planned to reduce the risks of stillbirth and can be associated with a variety of neonatal complications. Post-partum flare is common in all the rheumatic diseases.


Subject(s)
Pregnancy Complications , Rheumatic Diseases/complications , Autoimmune Diseases/complications , Autoimmune Diseases/diagnosis , Female , Fertility , Humans , Immunity, Maternally-Acquired , Pregnancy , Pregnancy Complications/diagnosis , Pregnancy Outcome , Prenatal Exposure Delayed Effects , Rheumatic Diseases/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...